Literature DB >> 11606936

The eflornithine story.

P E Coyne1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11606936     DOI： 10.1067/mjd.2001.117853

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  6 in total

1.  Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.

Authors:  Carl Amilon; Mikael Boberg; Joel Tarning; Angela Äbelö; Michael Ashton; Rasmus Jansson-Löfmark
Journal:  AAPS J       Date:  2022-03-25       Impact factor: 4.009

2.  Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.

Authors:  Seth M Schneider; Suzanne M Pritchard; George A Wudiri; Chasity E Trammell; Anthony V Nicola
Journal:  mBio       Date:  2019-05-14       Impact factor: 7.867

3.  Application of Hantzsch reaction for sensitive determination of eflornithine in cream, plasma and urine samples.

Authors:  Albandary Almahri; Mohamed A Abdel-Lateef
Journal:  R Soc Open Sci       Date:  2021-05-12       Impact factor: 2.963

4.  The death and life of the resurrection drug.

Authors:  Charles Ebikeme
Journal:  PLoS Negl Trop Dis       Date:  2014-07-10

Review 5.  Treatment options for second-stage gambiense human African trypanosomiasis.

Authors:  Gilles Eperon; Manica Balasegaram; Julien Potet; Charles Mowbray; Olaf Valverde; François Chappuis
Journal:  Expert Rev Anti Infect Ther       Date:  2014-09-10       Impact factor: 5.091

Review 6.  Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases.

Authors:  Nicole LoGiudice; Linh Le; Irene Abuan; Yvette Leizorek; Sigrid C Roberts
Journal:  Med Sci (Basel)       Date:  2018-02-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.